首页 > 市场调查报告书 > 製药

个人化医学

市场调查报告书

商品编码

1620527

个人化医疗生物标记市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Personalized Medicine Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月31日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球个人化医疗生物标记市场预计到2023 年价值159 亿美元，预计将实现显着成长，2024 年至2032 年复合年增长率预计为15.1%。、基因组学和蛋白质组学的进步以及向定制医疗保健解决方案的转变。随着医疗保健变得更加以患者为中心，个人化医疗生物标记透过实现精确、有针对性的护理而彻底改变了治疗方法。基因组定序和分子诊断的重大进展增强了识别疾病特异性生物标记的能力，从而实现了更量身定制的治疗策略。製药公司正在利用这些进步来开发具有更高功效和更少副作用的精准疗法，并改善患者的治疗效果和依从性。

按生物标记类型细分，市场包括基因组、蛋白质组和代谢生物标记等。基因组生物标记在 2023 年的收入高达 66 亿美元，凸显了它们在疾病检测、风险评估和治疗优化方面的重要性。来自基因分析的基因组标记可以深入了解遗传倾向，并且可以预测患者对特定治疗的反应，特别是在肿瘤学等领域。这些见解使医疗保健提供者能够设计出更有效的针对患者的治疗方法，提高治疗成功率并改善生活品质。

从应用来看，市场分为早期检测/筛检、诊断、治疗选择和监测。到 2023 年，诊断领域将占据 34.1% 的份额，对于早期、准确的疾病检测仍然至关重要。利用遗传、蛋白质组和代谢组等各种生物标誌物，个人化诊断为临床医生提供了有关疾病阶段和潜在治疗反应的宝贵见解。这对于管理肿瘤学、心臟病学和神经病学的病情尤其重要，及时介入是关键。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	159 亿美元
预测值	562 亿美元
复合年增长率	15.1%

在美国，个人化医疗生物标记市场预计将以15% 的复合年增长率增长，到2032 年将达到211 亿美元。这种增长得益于该国先进的医疗基础设施、大量的研发投资和这种增长得益于该国先进的医疗基础设施、大量的研发投资和积极采用精准医疗。联邦措施正在加速研究并促进资料整合，而慢性病的流行继续推动生物标记的需求。此外，顶级製药和生物技术公司与学术和政府机构之间的合作正在刺激生物标记开发的创新。患者意识的提高和对个性化治疗选择的需求推动了这一趋势，诊断和伴随治疗的利用率不断提高，以提高治疗效果并最大限度地减少不良反应。向治疗的不断发展，个人化医学生物标记市场有望大幅扩张重塑患者护理，提高治疗效率并满足患者个别需求。

产业生态系统分析
产业影响力
- 成长动力
  - 基因组学和蛋白质组学的进展
  - 慢性病盛行率上升
  - 标靶治疗的需求不断增长
- 产业陷阱与挑战
  - 开发成本高
  - 监理复杂性
成长潜力分析
监管环境
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：依生物标记类型，2021-2032 年

主要趋势
基因组
蛋白质体学
代谢
其他生物标记类型

第 6 章：市场估计与预测：按应用划分，2021-2032 年

主要趋势
早期发现/筛检
诊断
治疗选择
监控
其他应用

第 7 章：市场估计与预测：依疾病适应症，2021-2032 年

主要趋势
肿瘤学
神经病学
糖尿病
自体免疫疾病
心臟病学
其他适应症

第 8 章：市场估计与预测：依最终用途，2021-2032 年

主要趋势
医院和诊所
製药和生物技术公司
诊断实验室
其他最终用户

第 9 章：市场估计与预测：按地区，2021-2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
MEA
- 南非
- 沙乌地阿拉伯
- 阿联酋

第 10 章：公司简介

Abbott Laboratories
Bio-Rad Laboratories
Danaher
EKF Diagnostics Holdings
F. Hoffmann-La Roche
Illumina
Lifesign
Merck
Myriad Genetics
QIAGEN
Signosis
Singulex
Thermo Fisher Scientific

简介目录

Product Code: 12082

The Global Personalized Medicine Biomarkers Market, valued at USD 15.9 billion in 2023, is set for remarkable growth with a projected CAGR of 15.1% from 2024 to 2032. This market expansion is driven by increasing chronic disease rates, advancements in genomics and proteomics, and the shift toward customized healthcare solutions. As healthcare becomes more patient-centered, personalized medicine biomarkers revolutionize treatment by enabling precise, targeted care. Significant progress in genomic sequencing and molecular diagnostics has enhanced the ability to identify disease-specific biomarkers, enabling more tailored treatment strategies. Pharmaceutical companies are harnessing these advancements to develop precision therapies with greater efficacy and reduced side effects and improve patient outcomes and adherence.

Segmented by biomarker type, the market includes genomic, proteomic, and metabolic biomarkers, among others. Genomic biomarkers led with a substantial USD 6.6 billion in revenue in 2023, underscoring their importance in disease detection, risk evaluation, and treatment optimization. Genomic markers, derived from gene analysis, provide insights into genetic predispositions and can predict how patients respond to specific treatments, particularly in fields like oncology. These insights allow healthcare providers to devise more effective, patient-specific therapies, bolstering treatment success rates and improving quality of life.

In terms of applications, the market is divided into early detection/screening, diagnosis, treatment selection, and monitoring. The diagnostic segment held a 34.1% share in 2023 and remains essential for early and accurate disease detection. Leveraging various biomarkers, such as genetic, proteomic, and metabolomic, personalized diagnostics offer clinicians valuable insights into disease stages and potential therapeutic responses. This is especially critical in managing conditions in oncology, cardiology, and neurology, where timely intervention is key.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$15.9 Billion
Forecast Value	$56.2 Billion
CAGR	15.1%

In the U.S., the personalized medicine biomarkers market is anticipated to grow at a 15% CAGR, reaching USD 21.1 billion by 2032. This growth is supported by the country's advanced healthcare infrastructure, significant R&D investments, and proactive adoption of precision medicine. Federal initiatives are accelerating research and fostering data integration, while the prevalence of chronic diseases continues to drive biomarker demand. Additionally, collaboration between top pharmaceutical and biotech companies, with academic and government institutions is spurring innovations in biomarker development. Rising patient awareness and demand for personalized treatment options fuel this trend, with diagnostics and companion therapeutics seeing increased utilization to enhance treatment outcomes and minimize adverse effects.Overall, the personalized medicine biomarkers market is positioned for substantial expansion, as precision diagnostics and targeted therapies continue to reshape patient care, making treatment more efficient and aligned with individual patient needs.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advances in genomics and proteomics
  - 3.2.1.2 Rising prevalence of chronic diseases
  - 3.2.1.3 Growing demand for targeted therapies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High development costs
  - 3.2.2.2 Regulatory complexities
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Biomarker Type, 2021-2032 ($ Mn)

5.1 Key trends
5.2 Genomic
5.3 Proteomics
5.4 Metabolic
5.5 Other biomarker types

Chapter 6 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)

6.1 Key trends
6.2 Early detection/screening
6.3 Diagnosis
6.4 Treatment selection
6.5 Monitoring
6.6 Other applications

Chapter 7 Market Estimates & Forecast, By Disease Indication, 2021-2032 ($ Mn)

7.1 Key trends
7.2 Oncology
7.3 Neurology
7.4 Diabetes
7.5 Autoimmune diseases
7.6 Cardiology
7.7 Other indications

Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Hospitals and clinics
8.3 Pharmaceutical and biotechnology companies
8.4 Diagnostic labs
8.5 Other end users

Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 MEA
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE